US filing analysis · 10-K
Sorted by SEC acceptance time (filing date when unavailable). Page 7 · 30 shown · up to 30 per page
NEM
The company recognized a loss of $859 in Loss on assets held for sale for the year ended 2024, of which $160 and $699 related to Telfer and the disposal groups remaining as held for sale, respectively. A resulting tax impact of $255 was recognized, resulting in a total loss of $1,114 recognized in Loss on assets held for sale.
US filing analysisUS10-K · Annual reportPublished Oct 11, 2026 (UTC)SEC filing date Feb 21, 2025
NewmontNEM$94.68-5.37%
NDAQ
Nasdaq said it expects to incur approximately $140 million in pre-tax charges in connection with the expanded Adenza restructuring program. The company said it expects to achieve annual cost savings of $140 million by the end of 2025, inclusive of $80 million of net expense synergies related to the AxiomSL and Calypso acquisition.
US filing analysisUS10-K · Annual reportPublished Oct 11, 2026 (UTC)SEC filing date Feb 21, 2025
NasdaqNDAQ$103.01-0.90%
MS
Morgan Stanley said it reported net revenues of $61.8 billion in 2024, an increase of 14% compared with $54.1 billion in 2023, and net income applicable to Morgan Stanley of $13.4 billion in 2023, an increase of 47% compared with $9.1 billion in the prior year.
US filing analysisUS10-K · Annual reportPublished Oct 11, 2026 (UTC)SEC filing date Feb 21, 2025
Morgan StanleyMS$165.67-5.32%
MRNA
Moderna said that for the year ended December 31, 2024, it recognized net product sales of $3.1 billion from sales of its COVID and RSV vaccines, compared to $6.7 billion for 2023 and $18.4 billion for 2022. Loss per share was $(9.28) for 2024.
US filing analysisUS10-K · Annual reportPublished Oct 12, 2026 (UTC)SEC filing date Feb 21, 2025
ModernaMRNA$196-1.67%
MET
MetLife said net income available to common shareholders was $4.2 billion in 2024 compared with $1.4 billion in 2023, and adjusted earnings available to common shareholders was $5.8 billion in 2023 compared with $5.5 billion in the prior year.
US filing analysisUS10-K · Annual reportPublished Oct 11, 2026 (UTC)SEC filing date Feb 21, 2025
MetLifeMET$95.67-1.98%
LYV
Live Nation Entertainment said 2024 revenue increased $429 million, or 2%, to $23.2 billion, while operating income declined $260 million, or 24%, primarily related to Astroworld estimated loss contingencies of $455 million.
US filing analysisUS10-K · Annual reportPublished Oct 12, 2026 (UTC)SEC filing date Feb 21, 2025
Live Nation EntertainmentLYV$174.96-2.34%
KIM
Kimco Realty said net income available to common shareholders for fiscal 2024 was $375.7 million ($0.55 diluted per share), compared to $629.3 million ($1.02 per share) for fiscal 2023.
US filing analysisUS10-K · Annual reportPublished Oct 11, 2026 (UTC)SEC filing date Feb 21, 2025
Kimco RealtyKIM$25.37+0.12%
KEY
KeyCorp said Scotiabank entered into an Investment Agreement to make a strategic minority investment of approximately $2.8 billion at a fixed price of $17.17 per share, and following the final purchase on December 27, 2024, Scotiabank owns approximately 14.9% of the company's common stock.
US filing analysisUS10-K · Annual reportPublished Oct 11, 2026 (UTC)SEC filing date Feb 21, 2025
KeyCorpKEY$19.45-2.90%
JBHT
J.B. Hunt said consolidated operating revenues in 2024 decreased 5.8% to $12.09 billion, compared to $12.83 billion in 2023, and consolidated operating expenses decreased 4.9%, resulting in an operating ratio of 93.1% in 2023 compared to 92.3%.
US filing analysisUS10-K · Annual reportPublished Oct 12, 2026 (UTC)SEC filing date Feb 21, 2025
J.B. HuntJBHT$218.54-3.03%
IP
International Paper said full-year 2024 net earnings attributable to shareholders were $557 million ($1.57 per diluted share), compared with $288 million ($0.82 per diluted share) for full-year 2023.
US filing analysisUS10-K · Annual reportPublished Oct 11, 2026 (UTC)SEC filing date Feb 21, 2025
International PaperIP$30.36-2.41%
IDXX
IDEXX Laboratories said cash used by financing activities in 2024 was $878.1 million, compared to $442.0 million in 2023, with the increase driven by repurchases of common stock of $837.0 million in 2023 compared to $71.9 million in the prior year. The amount includes a 1% excise tax paid on certain stock repurchases.
US filing analysisUS10-K · Annual reportPublished Oct 12, 2026 (UTC)SEC filing date Feb 21, 2025
IDEXX LaboratoriesIDXX$676.29-1.94%
EXPD
Expeditors International said cash from operations in 2024 was $723 million, down $330 million from $1,053 million in 2023. The company cited a significant investment in working capital to finance its growth in the second half of 2024 as the reason for the decrease.
US filing analysisUS10-K · Annual reportPublished Oct 12, 2026 (UTC)SEC filing date Feb 21, 2025
Expeditors InternationalEXPD$192.56-0.30%
ESS
The company said 2024 Same-Property revenues increased $51.5 million, or 3.3%. Average rental rates rose 1.9% from $2,605 in 2023 to $2,655 in 2024, while occupancy decreased 0.4%.
US filing analysisUS10-K · Annual reportPublished Oct 11, 2026 (UTC)SEC filing date Feb 21, 2025
Essex Property TrustESS$269.65+0.10%
CVX
Chevron said U.S. upstream earnings increased by $3.5 billion in 2024 while international upstream earnings decreased by $2.3 billion. The company cited higher sales volumes of $2.2 billion and the absence of charges from decommissioning obligations for previously divested assets in the Gulf of America of $1.9 billion as factors for the U.S. increase.
US filing analysisUS10-K · Annual reportPublished Oct 12, 2026 (UTC)SEC filing date Feb 21, 2025
ChevronCVX$208.37+0.91%
CDW
CDW said Corporate segment net sales decreased $124 million (1.4%) and Public segment net sales decreased $148 million (1.8%) in 2024. Small Business segment net sales also decreased $33 million (2.1%).
US filing analysisUS10-K · Annual reportPublished Oct 12, 2026 (UTC)SEC filing date Feb 21, 2025
CDWCDW$161.96-3.37%
CBOE
Cboe Global Markets said revenues less cost of revenues for its Options segment for the year ended December 31, 2024 increased $90.1 million compared to the prior year, and operating income increased $27.1 million. The company cited a 8% increase in index options ADV and a 6% increase in multi-listed options RPC as factors.
US filing analysisUS10-K · Annual reportPublished Oct 12, 2026 (UTC)SEC filing date Feb 21, 2025
Cboe Global MarketsCBOE$357.75+0.02%
C
Citigroup reported net income of $12.7 billion, or $5.94 per share, for 2024, compared to $9.2 billion, or $4.04 per share, in the prior year, an increase of 37%. Revenues were $81.1 billion, up 3%, and operating expenses were $54.0 billion, down 4%.
US filing analysisUS10-K · Annual reportPublished Oct 11, 2026 (UTC)SEC filing date Feb 21, 2025
CitigroupC$110.62-4.04%
BAX
Baxter International said global net sales for 2024 totaled $10.64 billion, an increase of 3% on a reported basis and 3% on a constant currency basis compared to 2023. U.S. sales were $5.85 billion, up 1%, and international sales were $4.79 billion, up 5% on a reported basis.
US filing analysisUS10-K · Annual reportPublished Oct 11, 2026 (UTC)SEC filing date Feb 21, 2025
Baxter InternationalBAX$25.390.00%
ABT
Abbott said COVID-19 testing-related sales in 2024 totaled $747 million, continuing to decline from $1.6 billion in 2023 and $8.4 billion in 2022. The company said Medical Devices, Established Pharmaceutical and Nutritional businesses drove 2024 sales growth.
US filing analysisUS10-K · Annual reportPublished Oct 12, 2026 (UTC)SEC filing date Feb 21, 2025
Abbott LaboratoriesABT$103-0.84%
VICI
The company said net income attributable to common stockholders for 2024 increased 6.6% year-over-year to $2.7 billion, and diluted net income per share increased 3.3% to $2.56. AFFO increased 8.4% to $2.4 billion, and diluted AFFO per share increased 5.1% to $2.26.
US filing analysisUS10-K · Annual reportPublished Oct 12, 2026 (UTC)SEC filing date Feb 20, 2025
VICI PropertiesVICI$24.2+0.04%
TMO
Thermo Fisher Scientific said GAAP operating income margin and adjusted operating income margin decreased in 2024 due primarily to unfavorable business mix and strategic investments, partially offset by productivity improvements.
US filing analysisUS10-K · Annual reportPublished Oct 12, 2026 (UTC)SEC filing date Feb 20, 2025
Thermo Fisher ScientificTMO$669.54-2.79%
TER
Teradyne said Semiconductor Test revenues increased $166.7 million (8.5%) in 2024, driven primarily by higher tester sales for computing, ADAS and memory applications, while Robotics revenues decreased $10.4 million (2.8%), driven primarily by continued weakness in the Industrial Automation market.
US filing analysisUS10-K · Annual reportPublished Oct 12, 2026 (UTC)SEC filing date Feb 20, 2025
TeradyneTER$204.86-9.92%
PWR
The company said net cash provided by operating activities in 2024 was $2.08 billion, a 32.1% increase compared to 2023. In the same year, it used $1.75 billion of cash, net of cash acquired, for acquisitions and $54.2 million for dividends on common stock.
US filing analysisUS10-K · Annual reportPublished Oct 12, 2026 (UTC)SEC filing date Feb 20, 2025
Quanta ServicesPWR$559.03-4.83%
PPG
PPG Industries said net sales in 2024 were approximately $15.8 billion, a decrease of 2% compared to the prior year. The company cited declining sales volumes and the combination of unfavorable foreign currency translation and divestitures as factors, and noted that aerospace coatings achieved record sales.
US filing analysisUS10-K · Annual reportPublished Oct 12, 2026 (UTC)SEC filing date Feb 20, 2025
PPG IndustriesPPG$117.12-1.54%
KO
The Coca-Cola Company said net cash used in financing activities in 2024 was $6,910 million. In the same year, debt issuances were $12,061 million and debt payments were $9,533 million.
US filing analysisUS10-K · Annual reportPublished Oct 12, 2026 (UTC)SEC filing date Feb 20, 2025
The Coca-Cola CompanyKO$96.8+0.74%
IEX
IDEX said net sales for fiscal 2024 were $3,268.8 million, flat overall and down 2% organically, and diluted EPS were $6.64, down 15%.
US filing analysisUS10-K · Annual reportPublished Oct 11, 2026 (UTC)SEC filing date Feb 20, 2025
IDEXIEX$219.64-3.25%
GWW
W.W. Grainger said net sales for 2024 were $17,168 million, an increase of $690 million or 4% compared to the prior year. On a daily, organic constant currency basis, net sales increased 5%.
US filing analysisUS10-K · Annual reportPublished Oct 11, 2026 (UTC)SEC filing date Feb 20, 2025
W.W. GraingerGWW$1,357.35-4.67%
EFX
Equifax said consolidated revenue for 2024 increased 8% compared to 2023, with revenue growth across USIS, International and Workforce Solutions. The company explained that foreign exchange rate fluctuations decreased revenue by $105.5 million, or 2%.
US filing analysisUS10-K · Annual reportPublished Oct 11, 2026 (UTC)SEC filing date Feb 20, 2025
EquifaxEFX$177.19+0.39%
ED
Consolidated Edison said CECONY's electric operating revenues increased $639 million in 2024 compared with 2023, citing as major factors an increase in revenues from the electric rate plan of $558 million and a change in incentives earned under the earnings adjustment mechanisms of $18 million.
US filing analysisUS10-K · Annual reportPublished Oct 12, 2026 (UTC)SEC filing date Feb 20, 2025
Consolidated EdisonED$119.36+0.23%
DHR
Danaher said consolidated revenues for 2024 were flat compared with 2023 and core sales declined 1.5%. Acquisitions contributed 2.0% to sales, and the impact of currency translation decreased reported sales by 0.5%.
US filing analysisUS10-K · Annual reportPublished Oct 11, 2026 (UTC)SEC filing date Feb 20, 2025
DanaherDHR$220.36-3.16%
These reports are reference information based on public facts such as filings and prices. They do not recommend buying or selling any security.